| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
The Second Department of Pathology, Miyazaki Medical College, Miyazaki 889-1692 [H. K., R. H., H. I., M. K.], and Department of Biological Sciences, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama 226-0026 [N. K.], Japan
Activation of hepatocyte growth factor/scatter factor (HGF/SF) in the extracellular milieu is a critical limiting step in the HGF/SF-induced signaling pathway mediated by Met receptor tyrosine kinase, which has potentially important roles in tumor biology and progression. However, little is known concerning the regulation of HGF/SF activation in tumors. Immunoblot analysis revealed that the activation of HGF/SF was enhanced significantly in colorectal carcinoma tissues compared with the corresponding normal mucosa. Serum-free conditioned media of cultured human colorectal carcinoma cell lines contained HGF/SF-activating activity, and the addition of a single-chain precursor form of HGF/SF to the serum-free culture of these cells resulted in HGF/SF-dependent modulation of cellular phenotypes, such as increased scattering and enhanced secretion of vascular endothelial growth factor. This processing activity was enhanced by thrombin treatment but was inhibited significantly by a neutralizing antibody against HGF activator (HGFA), a factor XIIa-like serine proteinase believed to be expressed mainly in the liver. The activity was also inhibited by recombinant HGFA inhibitor type 1 (HAI-1). The presence of HGFA mRNA and secretion of HGFA protein were confirmed in the cell lines. Therefore, extrahepatic expression of HGFA in the colorectal carcinoma cells could be responsible for the single-chain HGF/SF-processing activity of the cells. We examined the expression of HGFA and HAI-1 in human colorectal mucosa and adenoma-carcinoma sequence. Immunohistochemically, HGFA was stained weakly in the normal enterocytes, and immunoreactivity was increased modestly in the neoplastic differentiation. The subcellular localization of HGFA immunoreactivity was altered in carcinoma cells showing basal or cell-stroma interface staining patterns, compared with normal and adenoma cells with a supranuclear or apical staining pattern. In contrast to HGFA, the expression of HAI-1 decreased significantly in carcinoma cells relative to the adjacent normal or adenoma cells, indicating that the net balance between HGFA and HAI-1 shifts in favor of HGFA in carcinomas. In fact, pro-HGFA and the active form of HGFA proteins increased in carcinoma tissue compared with the corresponding normal mucosa. It was concluded that HGFA is expressed in colorectal mucosa and tumors and could be involved in the activation of HGF/SF in colorectal carcinomas. Therefore, the balance between HGFA and HAI-1 could play an important role in the regulation of HGF/SF activity in colorectal carcinomas.
This article has been cited by other articles:
|
|
 |
|
  K. Nakamura, F. Abarzua, A. Hongo, J. Kodama, Y. Nasu, H. Kumon, and Y. Hiramatsu Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer Ann. Onc., January 1, 2009; 20(1): 63 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marchand-Adam, A. Fabre, A. A. Mailleux, J. Marchal, C. Quesnel, H. Kataoka, M. Aubier, M. Dehoux, P. Soler, and B. Crestani Defect of Pro-Hepatocyte Growth Factor Activation by Fibroblasts in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 58 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saleem, V. M. Adhami, W. Zhong, B. J. Longley, C.-Y. Lin, R. B. Dickson, S. Reagan-Shaw, D. F. Jarrard, and H. Mukhtar A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 217 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. M. Tjin, R. W. J. Groen, I. Vogelzang, P. W. B. Derksen, M. D. Klok, H. P. Meijer, S. van Eeden, S. T. Pals, and M. Spaargaren Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma Blood, January 15, 2006; 107(2): 760 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fan, T. D. Wu, W. Li, and D. Kirchhofer Identification of Hepatocyte Growth Factor Activator Inhibitor-1B as a Potential Physiological Inhibitor of Prostasin J. Biol. Chem., October 14, 2005; 280(41): 34513 - 34520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. M. Tjin, R. J. Bende, P. W. B. Derksen, A.-P. van Huijstee, H. Kataoka, M. Spaargaren, and S. T. Pals Follicular Dendritic Cells Catalyze Hepatocyte Growth Factor (HGF) Activation in the Germinal Center Microenvironment by Secreting the Serine Protease HGF Activator J. Immunol., September 1, 2005; 175(5): 2807 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tanaka, K. Nagaike, N. Takeda, H. Itoh, K. Kohama, T. Fukushima, S. Miyata, S. Uchiyama, S. Uchinokura, T. Shimomura, et al. Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1) Is Required for Branching Morphogenesis in the Chorioallantoic Placenta Mol. Cell. Biol., July 1, 2005; 25(13): 5687 - 5698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Knudsen, J. M. Lucas, L. Fazli, S. Hawley, S. Falcon, I. M. Coleman, D. B. Martin, C. Xu, L. D. True, M. E. Gleave, et al. Regulation of Hepatocyte Activator Inhibitor-1 Expression by Androgen and Oncogenic Transformation in the Prostate Am. J. Pathol., July 1, 2005; 167(1): 255 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P.M. Tjin, P. W.B. Derksen, H. Kataoka, M. Spaargaren, and S. T. Pals Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator Blood, October 1, 2004; 104(7): 2172 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tahara, A. Ido, S. Yamamoto, Y. Miyata, H. Uto, T. Hori, K. Hayashi, and H. Tsubouchi Hepatocyte Growth Factor Facilitates Colonic Mucosal Repair in Experimental Ulcerative Colitis in Rats J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 146 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kirchhofer, M. Peek, W. Li, J. Stamos, C. Eigenbrot, S. Kadkhodayan, J. M. Elliott, R. T. Corpuz, R. A. Lazarus, and P. Moran Tissue Expression, Protease Specificity, and Kunitz Domain Functions of Hepatocyte Growth Factor Activator Inhibitor-1B (HAI-1B), a New Splice Variant of HAI-1 J. Biol. Chem., September 19, 2003; 278(38): 36341 - 36349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Kang, M. Dolled-Filhart, I. T. Ocal, B. Singh, C.-Y. Lin, R. B. Dickson, D. L. Rimm, and R. L. Camp Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer Cancer Res., March 1, 2003; 63(5): 1101 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peek, P. Moran, N. Mendoza, D. Wickramasinghe, and D. Kirchhofer Unusual Proteolytic Activation of Pro-hepatocyte Growth Factor by Plasma Kallikrein and Coagulation Factor XIa J. Biol. Chem., November 27, 2002; 277(49): 47804 - 47809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Oberst, M. D. Johnson, R. B. Dickson, C.-Y. Lin, B. Singh, M. Stewart, A. Williams, A. al-Nafussi, J. F. Smyth, H. Gabra, et al. Expression of the Serine Protease Matriptase and Its Inhibitor HAI-1 in Epithelial Ovarian Cancer: Correlation with Clinical Outcome and Tumor Clinicopathological Parameters Clin. Cancer Res., April 1, 2002; 8(4): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
